Brief: NGM Bio Presents Phase 1 Safety And Pharmacokinetics Data For NGM621
13/11/2020 13:19
Nov 13 (Reuters) - NGM Biopharmaceuticals Inc NGM.O :
* NGM BIO PRESENTS PHASE 1 SAFETY AND PHARMACOKINETICS DATA
FOR
NGM621, AN ANTI-COMPLEMENT C3 ANTIBODY, IN PATIENTS WITH
GEOGRAPHIC ATROPHY AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY 2020
VIRTUAL
* NGM BIOPHARMACEUTICALS INC - IN STUDY, NGM621 WAS WELL
TOLERATED, WITH NO PATIENTS EXPERIENCING SERIOUS ADVERSE EVENTS
Source text for Eikon: ID:nGNX2cfYtp
Further company coverage: NGM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NGM Biopharmaceuticals
See all newsBrief: NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors